L
Laurent Knoops
Researcher at Cliniques Universitaires Saint-Luc
Publications - 81
Citations - 5631
Laurent Knoops is an academic researcher from Cliniques Universitaires Saint-Luc. The author has contributed to research in topics: Ruxolitinib & Mutation. The author has an hindex of 33, co-authored 81 publications receiving 4996 citations. Previous affiliations of Laurent Knoops include Netherlands Cancer Institute & Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire N. Harrison,Jean-Jacques Kiladjian,Haifa Kathrin Al-Ali,Heinz Gisslinger,Roger J. Waltzman,Viktoriya Stalbovskaya,Mari McQuitty,Deborah S. Hunter,Richard S. Levy,Laurent Knoops,Francisco Cervantes,Alessandro M. Vannucchi,Tiziano Barbui,Giovanni Barosi +13 more
TL;DR: Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.
Journal ArticleDOI
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes,Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Haifa Kathrin Al-Ali,Andres Sirulnik,Viktoriya Stalbovskaya,Mari McQuitty,Deborah S. Hunter,Richard S. Levy,Francesco Passamonti,Tiziano Barbui,Giovanni Barosi,Claire N. Harrison,Laurent Knoops,Heinz Gisslinger +14 more
TL;DR: In the ruxolitinib arm, with continued therapy, spleen volume reductions of ≥35% by magnetic resonance imaging were sustained for at least 144 weeks, with the probability of 50% (95% confidence interval [CI], 36-63) among patients achieving such degree of response, at the time of this analysis.
Journal ArticleDOI
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Elisabetta Flex,Valentina Petrangeli,Lorenzo Stella,Sabina Chiaretti,Tekla Hornakova,Laurent Knoops,Cristina Ariola,Valentina Fodale,Emmanuelle Clappier,Francesca Paoloni,Simone Martinelli,Alessandra Fragale,Massimo Sanchez,Simona Tavolaro,Monica Messina,Giovanni Cazzaniga,Andrea Camera,Giovanni Pizzolo,Assunta Tornesello,Marco Vignetti,Angela Battistini,Hélène Cavé,Bruce D. Gelb,Jean-Christophe Renauld,Andrea Biondi,Stefan N. Constantinescu,Robin Foà,Marco Tartaglia +27 more
TL;DR: It is reported that somatic mutations in JAK1 occur in individuals with acute lymphoblastic leukemia (ALL), and this kinase is pointed to as a target for the development of novel antileukemic drugs.
Journal ArticleDOI
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
Claire N. Harrison,Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Haifa Kathrin Al-Ali,Heinz Gisslinger,Laurent Knoops,Francisco Cervantes,Mark M. Jones,Kang Sun,Mari McQuitty,Viktoriya Stalbovskaya,Prashanth Gopalakrishna,T Barbui +12 more
TL;DR: It was shown that spleen volume reductions with ruxolitinib were maintained with continued therapy and may be associated with survival benefits and there was no unexpected increased incidence of adverse events with longer exposure.
Journal ArticleDOI
Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.
Annuska M. Glas,Laurent Knoops,Leonie J. M. J. Delahaye,Marie José Kersten,Robby E. Kibbelaar,L. F. A. Wessels,Ryan van Laar,J. Han van Krieken,Joke W. Baars,John M. M. Raemaekers,Philip M. Kluin,Laura J. van't Veer,Daphne de Jong +12 more
TL;DR: The identification of FL as an immunologically functional disease in which an interaction of the tumor cells and the functional composition of the microenvironment determines the clinical behavior is supported.